{"count": 4, "results": [{"_id": "36734733", "pmid": 36734733, "title": "Efficacy and safety of single pill combination of amlodipine and valsartan in hypertensive Saudi patients.", "journal": "Eur Rev Med Pharmacol Sci", "authors": ["Alluhabi SI", "Alkreathy HM", "Alharthi TS", "Alqarni F", "Alama MN", "Ahmad A", "Alrafiah AR", "Damanhouri ZA"], "date": "2023-01-01T00:00:00Z", "doi": "10.26355/eurrev_202301_31085", "meta_date_publication": "2023 Jan", "meta_volume": "27", "meta_issue": "2", "meta_pages": "773-786", "score": 50266.305, "text_hl": "RESULTS: According to the results, taking @<m>CHEMICAL_Amlodipine_Valsartan_Drug_Combination</m> @CHEMICAL_MESH:D000068838 @@@Aml/Val@@@ SPC significantly lowered all @SPECIES_9606 @@@patients@@@' baseline systolic and diastolic blood pressure readings by -17.97 and 8.58 mmHg, respectively. 43.4% of @SPECIES_9606 @@@patients@@@ successfully met their BP therapeutic objectives by bringing their blood pressure levels back to normal, including 51.4% of @SPECIES_9606 @@@patients@@@ under 65, 39.3% of @SPECIES_9606 @@@patients@@@ with @DISEASE_Renal_Insufficiency_Chronic @DISEASE_MESH:D051436 @@@chronic kidney disease@@@, and 26.2% of @<m>DISEASE_Diabetes_Mellitus</m> @DISEASE_MESH:D003920 @@@diabetic@@@ @SPECIES_9606 @@@patients@@@. ", "citations": {"NLM": "Alluhabi SI, Alkreathy HM, Alharthi TS, Alqarni F, Alama MN, Ahmad A, Alrafiah AR, Damanhouri ZA. Efficacy and safety of single pill combination of amlodipine and valsartan in hypertensive Saudi patients. Eur Rev Med Pharmacol Sci. 2023 Jan;27(2):773-786. PMID: 36734733", "BibTeX": "@article{36734733, title={Efficacy and safety of single pill combination of amlodipine and valsartan in hypertensive Saudi patients.}, author={Alluhabi SI and Alkreathy HM and Alharthi TS and Alqarni F and Alama MN and Ahmad A and Alrafiah AR and Damanhouri ZA}, journal={Eur Rev Med Pharmacol Sci}, volume={27}, number={2}, pages={773-786}}"}}, {"_id": "25653536", "pmid": 25653536, "pmcid": "PMC4309775", "title": "Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups", "journal": "Vasc Health Risk Manag", "authors": ["Assaad-Khalil SH", "Najem R", "Sison J", "Kitchlew AR", "Cho B", "Ueng KC", "DiTommaso S", "Shete A"], "date": "2015-01-21T00:00:00Z", "doi": "10.2147/VHRM.S76599", "meta_date_publication": "2015", "meta_volume": "11", "meta_issue": "", "meta_pages": "71-8", "score": 50090.016, "text_hl": "In the large multiethnic EXCITE study, conducted in a real-world setting, @<m>CHEMICAL_Amlodipine_Valsartan_Drug_Combination</m> @CHEMICAL_MESH:D000068838 @@@Aml/Val@@@ and @<m>CHEMICAL_Amlodipine_Valsartan_Drug_Combination</m> @CHEMICAL_MESH:D000068838 @@@Aml/Val@@@/HCT SPCs were effective in high-risk @SPECIES_9606 @@@patients@@@ with @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertension@@@, including the elderly, and @SPECIES_9606 @@@patients@@@ with @DISEASE_Obesity @DISEASE_MESH:D009765 @@@obesity@@@, @<m>DISEASE_Diabetes_Mellitus</m> @DISEASE_MESH:D003920 @@@diabetes@@@, or @DISEASE_Isolated_Systolic_Hypertension @DISEASE_MESH:D000092244 @@@ISH@@@. ", "citations": {"NLM": "Assaad-Khalil SH, Najem R, Sison J, Kitchlew AR, Cho B, Ueng KC, DiTommaso S, Shete A. Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups Vasc Health Risk Manag. 2015;11():71-8. PMID: 25653536", "BibTeX": "@article{25653536, title={Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups}, author={Assaad-Khalil SH and Najem R and Sison J and Kitchlew AR and Cho B and Ueng KC and DiTommaso S and Shete A}, journal={Vasc Health Risk Manag}, volume={11}, pages={71-8}}"}}, {"_id": "23452532", "pmid": 23452532, "title": "[Cost-effectiveness analysis of fixed dose antihypertensive drugs].", "journal": "Semergen", "authors": ["García Ruiz AJ", "Divisón Garrote JA", "García-Agua Soler N", "Morata García de la Puerta F", "Montesinos Gálvez AC", "Avila Lachica L"], "date": "2013-03-01T00:00:00Z", "doi": "10.1016/j.semerg.2012.05.011", "meta_date_publication": "2013 Mar", "meta_volume": "39", "meta_issue": "2", "meta_pages": "77-84", "score": 50053.703, "text_hl": "MAIN OUTCOME MEASURES: Cost per mmHg reduction in BP, percentage of reduction necessary to achieve the therapeutic goals for @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertension@@@ control and cost, and finally quantity and quality of life gained with these treatments in @SPECIES_9606 @@@patients@@@ with @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertension@@@, @<m>DISEASE_Diabetes_Mellitus</m> @DISEASE_MESH:D003920 @@@diabetes@@@. RESULTS: We studied three fixed-dose combinations: @CHEMICAL_Amlodipine @CHEMICAL_MESH:D017311 @@@amlodipine@@@/@CHEMICAL_olmesartan @CHEMICAL_MESH:C437965 @@@olmesartan@@@, @<m>CHEMICAL_Amlodipine_Valsartan_Drug_Combination</m> @CHEMICAL_MESH:D000068838 @@@amlodipine/valsartan@@@ and @CHEMICAL_manidipine @CHEMICAL_MESH:C054218 @@@manidipine@@@/@CHEMICAL_delapril @CHEMICAL_MESH:C047759 @@@delapril@@@. ", "citations": {"NLM": "García Ruiz AJ, Divisón Garrote JA, García-Agua Soler N, Morata García de la Puerta F, Montesinos Gálvez AC, Avila Lachica L. [Cost-effectiveness analysis of fixed dose antihypertensive drugs]. Semergen. 2013 Mar;39(2):77-84. PMID: 23452532", "BibTeX": "@article{23452532, title={[Cost-effectiveness analysis of fixed dose antihypertensive drugs].}, author={García Ruiz AJ and Divisón Garrote JA and García-Agua Soler N and Morata García de la Puerta F and Montesinos Gálvez AC and Avila Lachica L}, journal={Semergen}, volume={39}, number={2}, pages={77-84}}"}}, {"_id": "23011292", "pmid": 23011292, "title": "Additive effects of cilnidipine and angiotensin II receptor blocker in preventing the progression of diabetic nephropathy in diabetic spontaneously hypertensive rats.", "journal": "Clin Exp Nephrol", "authors": ["Aritomi S", "Niinuma K", "Ogawa T", "Konda T", "Nitta K"], "date": "2013-02-01T00:00:00Z", "doi": "10.1007/s10157-012-0677-4", "meta_date_publication": "2013 Feb", "meta_volume": "17", "meta_issue": "1", "meta_pages": "41-50", "score": 50043.44, "text_hl": "METHODS: @<m>DISEASE_Diabetes_Mellitus</m> @DISEASE_MESH:D003920 @@@Diabetes@@@ was induced in 9-week-old male spontaneously @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertensive@@@ @SPECIES_10116 @@@rats@@@ by intraperitoneally injecting them with @CHEMICAL_Streptozocin @CHEMICAL_MESH:D013311 @@@streptozotocin@@@ (40 mg/kg twice) and the @SPECIES_10116 @@@rats@@@ (8 per group) were randomly assigned to receive @CHEMICAL_Valsartan @CHEMICAL_MESH:D000068756 @@@valsartan@@@ (@CHEMICAL_Valsartan @CHEMICAL_MESH:D000068756 @@@Val@@@), @CHEMICAL_cilnidipine @CHEMICAL_MESH:C065927 @@@Cil +@@@ @CHEMICAL_Valsartan @CHEMICAL_MESH:D000068756 @@@Val@@@, @<m>CHEMICAL_Amlodipine_Valsartan_Drug_Combination</m> @CHEMICAL_MESH:D000068838 @@@Aml + Val@@@, or vehicle for 8 weeks through a gastric tube. ", "citations": {"NLM": "Aritomi S, Niinuma K, Ogawa T, Konda T, Nitta K. Additive effects of cilnidipine and angiotensin II receptor blocker in preventing the progression of diabetic nephropathy in diabetic spontaneously hypertensive rats. Clin Exp Nephrol. 2013 Feb;17(1):41-50. PMID: 23011292", "BibTeX": "@article{23011292, title={Additive effects of cilnidipine and angiotensin II receptor blocker in preventing the progression of diabetic nephropathy in diabetic spontaneously hypertensive rats.}, author={Aritomi S and Niinuma K and Ogawa T and Konda T and Nitta K}, journal={Clin Exp Nephrol}, volume={17}, number={1}, pages={41-50}}"}}]}